Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Social Science & Medicine (1982)
|
August 7, 2022
Producing paramedicine: Case studies in the medical labor process
Josh Seim, Michael Corman, Leo McCann
The Journal of Biological Chemistry
|
October 4, 2019
A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity
Pathricia Veronica Tilstam, Georgios Pantouris, Michael Corman, et al.
Digital Health
|
July 21, 2025
Computer-based training for cognitive behavioral therapy (CBT4CBT): A mixed methods investigation
Danielle Downie, Alina Patel, Michael Corman, et al.
BMJ Open
|
December 16, 2022
Peer support and online cognitive behavioural therapy for substance use concerns: protocol for a randomised controlled trial
Lena C Quilty, Jeffrey D Wardell, Gord Garner, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
May 24, 2024
Computer-Based Training for Cognitive Behavioural Therapy for Substance Use Disorder: A Randomized Controlled Trial Including Quantitative and Qualitative Health and Economic Outcomes: Formation informatisée pour la thérapie cognitivo-comportementale pour les troubles liés à l'usage de substances : un essai randomisé contrôlé y compris les résultats quantitatifs et qualitatifs en matière de santé et d'économie
Alina Patel, Michael Corman, Claire de Oliveira, et al.
Journal of Medicinal Chemistry
|
July 28, 2009
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia
Patrick R Verhoest, Douglas S Chapin, Michael Corman, et al.
Journal of Medicinal Chemistry
|
July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders
Patrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry
|
November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy
Patrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Social Science & Medicine (1982)
|
August 7, 2022
Producing paramedicine: Case studies in the medical labor process
Josh Seim, Michael Corman, Leo McCann
The Journal of Biological Chemistry
|
October 4, 2019
A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity
Pathricia Veronica Tilstam, Georgios Pantouris, Michael Corman, et al.
Digital Health
|
July 21, 2025
Computer-based training for cognitive behavioral therapy (CBT4CBT): A mixed methods investigation
Danielle Downie, Alina Patel, Michael Corman, et al.
BMJ Open
|
December 16, 2022
Peer support and online cognitive behavioural therapy for substance use concerns: protocol for a randomised controlled trial
Lena C Quilty, Jeffrey D Wardell, Gord Garner, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
May 24, 2024
Computer-Based Training for Cognitive Behavioural Therapy for Substance Use Disorder: A Randomized Controlled Trial Including Quantitative and Qualitative Health and Economic Outcomes: Formation informatisée pour la thérapie cognitivo-comportementale pour les troubles liés à l'usage de substances : un essai randomisé contrôlé y compris les résultats quantitatifs et qualitatifs en matière de santé et d'économie
Alina Patel, Michael Corman, Claire de Oliveira, et al.
Journal of Medicinal Chemistry
|
July 28, 2009
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia
Patrick R Verhoest, Douglas S Chapin, Michael Corman, et al.
Journal of Medicinal Chemistry
|
July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders
Patrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry
|
November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy
Patrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Page
of 1